Eledon Pharmaceuticals Inc.

3.27
0.03 (0.93%)
Apr 25, 2025, 3:59 PM - Market open
0.93%
Created with Highcharts 11.4.39 AM4 PM10 AM12 PM1 PM2 PM3.23.253.33.353.4
Bid 3.02
Market Cap 195.81M
Revenue (ttm) 192K
Net Income (ttm) -35.32M
EPS (ttm) -0.75
PE Ratio (ttm) -4.36
Forward PE -3.15
Analyst Buy
Ask 3.53
Volume 487
Avg. Volume (20D) 228,721
Open 3.27
Previous Close 3.24
Day's Range 3.27 - 3.27
52-Week Range 2.00 - 5.54
Beta 0.67

About ELDN

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical tri...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 17, 2014
Employees 31
Stock Exchange NASDAQ
Ticker Symbol ELDN
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for ELDN stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 389.30% from the latest price.

Created with Highcharts 11.4.3StrongSellSellHoldBuyStrongBuy012
Price Target: $16
(389.30% upside)
Analyst Consensus: Buy
Stock Forecasts
5 months ago
-11.41%
Eledon Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription